PPT-Aspirin (n = 6,610) Ticagrelor

n 6589 SOCRATES Primary outcome death MI or stroke for ticagrelor vs aspirin 67 vs 75 HR 089 95 CI 078101 p 007 Death 10 vs 09 p 036 All strokes 59 vs 68 . safety study . of . ticagrelor's. degradation combining . LC-MS and . in . silico. approach. H. SADOU YAYE*, B. DO, N. YAGOUBI. * . Pharmacist at . Pitié-Salpêtrière. Hospital (Paris) . P. hD student – University Paris . PLAT. elet Inhibition and patient . O. utcomes trial. Outcomes in patients with a Planned Invasive Strategy. The PLATO trial was funded by AstraZeneca. Invasive. PLATO background. In STEMI and UA/NSTEMI, current guidelines recommend 12 months of aspirin and clopidogrel. Announcements . Thank you attending the ACCP Cardiology PRN Journal Club. Thank you if you attended last time or have been attending. I have created a PB Works Site that will house our recorded calls, handouts, and Summary/Q&A documents. The . The sensation of pain – our ability to perceive pain is one of our best defense mechanisms. . Pain allows us to act in a way that reduces further damage to our bodies. For example, removing the hand from a hot plate or not being able to continue running after pulling a muscle.. Giuseppe . Biondi-Zoccai. , MD. Sapienza University . of. . Rome. , Italy. giuseppe.biondizoccai@uniroma1.it. Learning. . goals. Scope . of. the . problem. Prasugrel. Ticagrelor. Reconciling. the . Associate Professor of Clinical Pharmacy,. SBMU. CLASSIFICATION OF ANTIPLATELET AGENTS. Cyclooxygenase inhibitors. Aspirin. Platelet . P2Y12 receptor . blockers. clopidogrel, . ticlopidine. , . ticagrelor. rin or A. L. one . I. n Hi. GH. -Risk Patients After Coronary In. T. ervention. Roxana Mehran, MD. on behalf of the TWILIGHT Investigators. Icahn School of Medicine at Mount Sinai, New York, NY. . ClinicalTrials.gov Number: NCT02270242. coronary intervention PCI1920 As new antithrombotic drugs DABE in combination with ticagrelor oers an additional option to substitute warfarin regimen with the expectation of decreasing the bleeding r ORIGIN. Pierre . Amarenco. , Hans . Denison. , . Scott R. Evans, Anders . Himmelmann. , Stefan James, Mikael . Knutsson. , . Per . Ladenvall. , Carlos . A. Molina. , . Yongjun. Wang. , S. . Claiborne . March 28, 2022. Disclosures. Present Research/Grant Funding. Janssen/Johnson & Johnson. CSL Behring. SCAD Alliance. Baim. Institute. Patents and Stocks: . None. Equity: . nference. , Inc. . Dyad Medical. rd. . 2021 . Steve Williams. Lead Clinical Pharmacist PrescQIPP Practice Plus. Agenda. Time. Title. Presenter. 12.45. Welcome , introduction and reflections . STOP, THINK, RE-FOCUS. Steve Williams . CrCl. : creatinine clearance, CTO: chronic total occlusion, DAPT: dual antiplatelet therapy, DOAC: direct oral anticoagulant, . eDAN. : electronic discharge advice notification, GFR: glomerular filtration rate, HF: heart failure, INR: international normalised ratio, LHP: Leeds Health Pathways, LTHT: Leeds Teaching Hospitals NHS Trust, LV: left ventricular, MACE: major adverse cardiovascular event, MI: myocardial infarction, NICE: National Institute for Health and Care Excellence, NSTEMI: non-ST segment elevation myocardial infarction, STEMI: ST segment elevation myocardial infarction, OD: once daily, PAD: peripheral arterial disease, P2Y12: platelet receptor for adenosine diphosphate PCI: percutaneous coronary intervention, PPI: proton pump inhibitor, SPC: summary of product characteristics, TIA: transient ischaemic attack.. Luis Ortega-Paz, MD, PhD. 1. ; Francesco Franchi, MD. 1. ; Fabiana Rollini, MD1, Mattia Galli, MD. 1. ,. 2. Latonya Been, AAS. 1. , Ghussan Ghanem, MD. 1. , . Awss. . Shalhoub. , MD. 1. , Tiffany Ossi, MD. Principal Results From the Double-blind, Placebo-controlled ULTIMATE-DAPT Trial. Gregg W Stone MD. Icahn School of Medicine at Mount Sinai. on behalf of Shao-Liang Chen and the ULTIMATE-DAPT Investigators.